{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:55:04Z","timestamp":1791266104595,"version":"4.1.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>B7-H3 (CD276) is broadly overexpressed across solid tumors and plays active roles in immune evasion, tumor angiogenesis, and metabolic reprogramming. As B7-H3-directed antibody\u2013drug conjugates chimeric antigen receptor T-cell therapies, and radioimmunotherapy agents advance through clinical trials, non-invasive whole-body imaging of B7-H3 expression has become a pressing clinical need. Tissue biopsy with IHC cannot capture systemic target heterogeneity, and the recent IDeate-PanTumor01 trial found no correlation between baseline B7-H3 H-score and response to ifinatamab deruxtecan\u2014illustrating the gap that molecular imaging must fill. This mini review surveys B7-H3-targeted imaging agents by scaffold class\u2014antibodies, affibodies, nanobodies, and bicyclic peptides\u2014and examines radioimmunotherapy platforms that couple PET-based dosimetry with targeted radionuclide delivery.<\/jats:p>","DOI":"10.3389\/fphar.2026.1923470","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:21:52Z","timestamp":1791264112000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["B7-H3 molecular imaging for the era of pan-cancer targeted therapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Baoyan","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Occupational Pulmonology, Shandong First Medical University Affiliated Occupational Disease Hospital (Shandong Occupational Disease Hospital)","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kewen","family":"He","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.ccell.2026.01.005","article-title":"Male-biased Yap1-Cd276\/B7-H3 axis for immune evasion in medulloblastoma","volume":"44","author":"Abdelfattah","year":"2026","journal-title":"Cancer Cell"},{"key":"B2","doi-asserted-by":"publisher","first-page":"30018","DOI":"10.1074\/jbc.M115.679852","article-title":"Humanized affinity-matured monoclonal antibody 8H9 has potent antitumor activity and binds to FG loop of tumor antigen B7-H3","volume":"290","author":"Ahmed","year":"2015","journal-title":"J. Biol. Chem."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2026.03.025","article-title":"PET molecular imaging and theranostics in lung diseases: making precision medicine a reality","author":"Assadi","year":"2026","journal-title":"Chest"},{"key":"B4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1021\/acschembio.2c00828","article-title":"Enzymatic macrolactamization of mRNA display libraries for inhibitor selection","volume":"18","author":"Bowler","year":"2023","journal-title":"ACS Chem. Biol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1683674","DOI":"10.3389\/fimmu.2025.1683674","article-title":"Immunological mechanisms and antibody-drug conjugates targeting B7-H3 and B7-H4 in ovarian cancer","volume":"16","author":"Brown","year":"2025","journal-title":"Front. Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.7150\/thno.25575","article-title":"Molecular imaging of T cell co-regulator factor B7-H3 with (89)Zr-DS-5573a","volume":"8","author":"Burvenich","year":"2018","journal-title":"Theranostics"},{"key":"B7","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.tips.2025.08.008","article-title":"The B7-H3 (CD276) pathway: emerging biology and clinical therapeutics","volume":"46","author":"Corrigan","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/978-1-0716-3499-8_10","article-title":"Radiolabeled affibody molecules for PET imaging","volume":"2729","author":"Da Pieve","year":"2024","journal-title":"Methods Mol. Biol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"118769","DOI":"10.1016\/j.ejmech.2026.118769","article-title":"Emerging (18)F labeling strategies for peptide-based PET tracers: a review of recent technological advances","volume":"309","author":"Diao","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40478-021-01167-w","article-title":"The expression of B7-H3 isoforms in newly diagnosed glioblastoma and recurrence and their functional role","volume":"9","author":"Digregorio","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"key":"B11","doi-asserted-by":"publisher","first-page":"130884","DOI":"10.1016\/j.bbagen.2025.130884","article-title":"Nanobody-based imaging: advancing precision in molecular diagnostics","volume":"1870","author":"Eftekhari","year":"2026","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.3390\/biomedicines12051088","article-title":"Affibody PET imaging of HER2-Expressing cancers as a key to guide HER2-Targeted therapy","volume":"12","author":"Eissler","year":"2024","journal-title":"Biomedicines"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-4767","article-title":"Preclinical activity of the B7-H3- targeting antibody-drug conjugate (Adc) vobramitamab duocarmazine (Vobra duo) in pediatric solid tumors","author":"Favours","year":"2026","journal-title":"Clin. Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.jconrel.2025.01.030","article-title":"Unraveling the dynamics of B7-H3-targeting therapeutic antibodies in cancer through PET imaging and antibody pharmacokinetics","volume":"379","author":"Fernandes","year":"2025","journal-title":"J. Control Release"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e2431712","DOI":"10.2214\/ajr.24.31712","article-title":"Whole-Body multiparametric PET in clinical oncology: current status, challenges, and opportunities","volume":"223","author":"Fraum","year":"2024","journal-title":"AJR Am. J. Roentgenol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.3390\/ph18101477","article-title":"Design and preclinical validation of an Anti-B7-H3-Specific radiotracer: a non-invasive imaging tool to guide B7-H3-Targeted therapies","volume":"18","author":"Funeh","year":"2025","journal-title":"Pharm. (Basel)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"5370","DOI":"10.7150\/thno.123285","article-title":"Anti-cancer immune priming with beta-radioligand therapy using a novel high affinity antibody selectively targeting the 4Ig-Isoform of B7-H3","volume":"16","author":"Glazer","year":"2026","journal-title":"Theranostics"},{"key":"B18","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2147\/itt.s507522","article-title":"Tumor immunotherapy targeting B7-H3: from mechanisms to clinical applications","volume":"14","author":"Guo","year":"2025","journal-title":"Immunotargets Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/s1470-2045(25)00733-8","article-title":"Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1\/2 trial","volume":"27","author":"Johnson","year":"2026","journal-title":"Lancet Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1158\/1078-0432.ccr-20-2584","article-title":"B7-H3: an attractive target for antibody-based immunotherapy","volume":"27","author":"Kontos","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13045-022-01383-4","article-title":"Phase 1 study of intraventricular (131)I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies","volume":"15","author":"Kramer","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"967","DOI":"10.2147\/itt.s534666","article-title":"B7-H3\/CD276: novel immune checkpoint and jack of all trades","volume":"14","author":"Larkin","year":"2025","journal-title":"Immunotargets Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"107371","DOI":"10.1016\/j.ejps.2025.107371","article-title":"Preclinical evaluation of (89)Zr\/(177)Lu-labelled anti-B7-H3 monoclonal antibody for theranostics in B7-H3-positive liver cancer","volume":"220","author":"Liang","year":"2026","journal-title":"Eur. J. Pharm. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"101232","DOI":"10.1016\/j.tranon.2021.101232","article-title":"Effective killing of cells expressing CD276 (B7-H3) by a bispecific T cell engager based on a new fully human antibody","volume":"14","author":"Liu","year":"2021","journal-title":"Transl. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"22384","DOI":"10.1021\/acsami.5c01451","article-title":"Molecular imaging of B7-H3-Targeting bispecific T cell-engaging antibody MGD009 in glioblastoma models","volume":"17","author":"Liu","year":"2025","journal-title":"ACS Appl. Mater Interfaces"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1625813","DOI":"10.3389\/fimmu.2025.1625813","article-title":"Dual T\/NK cell engagement via B7-H6-targeted bispecific antibodies and IL-15 eradicates chemo-resistant solid tumors","volume":"16","author":"Ma","year":"2025","journal-title":"Front. Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12916-024-03831-z","article-title":"Translation of PET radiotracers for cancer imaging: recommendations from the National Cancer Imaging Translational Accelerator (NCITA) consensus meeting","volume":"23","author":"McAteer","year":"2025","journal-title":"BMC Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.3390\/cells14151209","article-title":"B7-H3 in cancer immunotherapy-prospects and challenges: a review of the literature","volume":"14","author":"Mielcarska","year":"2025","journal-title":"Cells"},{"key":"B29","doi-asserted-by":"publisher","first-page":"103726","DOI":"10.1016\/j.jtho.2026.103726","article-title":"Antibody-Drug conjugates in SCLC: DLL3, B7-H3, TROP2, and beyond","volume":"21","author":"Monaca","year":"2026","journal-title":"J. Thorac. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/cas.12915","article-title":"Development of DS-5573a: a novel afucosylated mAb directed at B7-H3 with potent antitumor activity","volume":"107","author":"Nagase-Zembutsu","year":"2016","journal-title":"Cancer Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.3390\/pharmaceutics14091780","article-title":"Evaluation of an affibody-based binder for imaging of immune check-point molecule B7-H3","volume":"14","author":"Oroujeni","year":"2022","journal-title":"Pharmaceutics"},{"key":"B32","doi-asserted-by":"publisher","first-page":"108384","DOI":"10.1016\/j.nucmedbio.2023.108384","article-title":"Evaluation of affinity matured Affibody molecules for imaging of the immune checkpoint protein B7-H3","author":"Oroujeni","year":"2023","journal-title":"Nucl. Med. Biol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s41181-024-00261-3","article-title":"Comparison of approaches for increasing affinity of affibody molecules for imaging of B7-H3: dimerization and affinity maturation","volume":"9","author":"Oroujeni","year":"2024","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e013356","DOI":"10.1136\/jitc-2025-013356","article-title":"Multiomic analysis of colorectal adenocarcinoma reveals a new subtype of myofibroblastic cancer-associated fibroblasts that express high levels of B7-H3 and have poor-prognosis value","volume":"14","author":"Picard","year":"2026","journal-title":"J. Immunother. Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/978-3-032-15314-2_4","article-title":"Total body PET","volume":"224","author":"Providencia","year":"2026","journal-title":"Recent Results Cancer Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"6132","DOI":"10.7150\/thno.125878","article-title":"Integrated radio-theranostics using a [(89)Zr]Zr-\/[(177)Lu]Lu-labeled B7-H3 antibody-drug conjugate for prostate cancer","volume":"16","author":"Qiu","year":"2026","journal-title":"Theranostics"},{"key":"B37","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1021\/cbmi.4c00030","article-title":"Peptide PET imaging: a review of recent developments and a look at the future of radiometal-labeled peptides in medicine","volume":"2","author":"Shabsigh","year":"2024","journal-title":"Chem. Biomed. Imaging"},{"key":"B38","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1089\/cbr.2025.0005","article-title":"Applications of nanobodies in biological imaging","volume":"40","author":"Sheng","year":"2025","journal-title":"Cancer Biother Radiopharm."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/S1470-2045(18)30322-X","article-title":"Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial","volume":"19","author":"Souweidane","year":"2018","journal-title":"Lancet Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.2967\/jnumed.124.269349","article-title":"Standardization of PET\/CT performance requirements for whole-body quantitative imaging: an international proposal","volume":"66","author":"Sunderland","year":"2025","journal-title":"J. Nucl. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"651","DOI":"10.3390\/cancers12030651","article-title":"Affibody molecules as targeting vectors for PET imaging","volume":"12","author":"Tolmachev","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B42","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1021\/acsptsci.4c00539","article-title":"Impact of radiometal chelates on in vivo visualization of immune checkpoint protein using radiolabeled affibody molecules","volume":"8","author":"Tolmachev","year":"","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1021\/acsptsci.5c00320","article-title":"Preclinical positron emission tomography imaging of B7-H3 expression using affibody molecules labeled with Gallium-68","volume":"8","author":"Tolmachev","year":"","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.3390\/ijms27041713","article-title":"Efficient (68)Ga labeling of a B7-H3-Targeting affibody molecule via Acyclic Tris(hydroxypyridinone) chelator: effects on biodistribution in a preclinical model","volume":"27","author":"Tolmachev","year":"2026","journal-title":"Int. J. Mol. Sci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"101082","DOI":"10.1016\/j.jpha.2024.101082","article-title":"Peptide-based immuno-PET\/CT monitoring of dynamic PD-L1 expression during glioblastoma radiotherapy","volume":"15","author":"Wang","year":"","journal-title":"J. Pharm. Anal."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.3390\/ph18111669","article-title":"Recent progress on affibody-based supramolecular architectures: moving from monomeric constructs to multivalent assemblies","volume":"18","author":"Wang","year":"","journal-title":"Pharm. (Basel)"},{"key":"B47","doi-asserted-by":"publisher","first-page":"101202","DOI":"10.1016\/j.drup.2025.101202","article-title":"Peptide-based PET\/CT imaging visualizes PD-L1-driven radioresistance in glioblastoma","volume":"79","author":"Wang","year":"","journal-title":"Drug Resist Updat"},{"key":"B48","doi-asserted-by":"publisher","first-page":"218526","DOI":"10.1016\/j.canlet.2026.218526","article-title":"Molecular PET imaging of tumor-associated macrophages in precision oncology","volume":"650","author":"Wang","year":"","journal-title":"Cancer Lett."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-026-05151-5","article-title":"Precision theranostics in oncology: integrating antibody-drug conjugates, radioimmunotherapy, and immuno-PET for adaptive cancer care","author":"Wang","year":"","journal-title":"Discov. Oncol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e186388","DOI":"10.1172\/jci186388","article-title":"A whole-body imaging technique for tumor-specific diagnostics and screening of B7H3-targeted therapies","volume":"135","author":"Xia","year":"2025","journal-title":"J. Clin. Invest"},{"key":"B51","doi-asserted-by":"publisher","first-page":"6275","DOI":"10.1158\/0008-5472.CAN-08-4517","article-title":"MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors","volume":"69","author":"Xu","year":"2009","journal-title":"Cancer Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1021\/polymscitech.5c00080","article-title":"Advances in nanobody-based platforms for precision cancer diagnosis and therapy","volume":"1","author":"Yuan","year":"2025","journal-title":"Polym. Sci. Technol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1751400","DOI":"10.3389\/fimmu.2026.1751400","article-title":"From mechanism to clinical: research evolution and hotspot analysis of CD276\/B7-H3 in cancer immunotherapy","volume":"17","author":"Zhai","year":"2026","journal-title":"Front. Immunol."},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6c00961","article-title":"Development and preclinical evaluation of (68)Ga-Labeled B7-H3-Specific bicyclic peptides as Immuno-PET tracers for oncology","author":"Zhang","year":"2026","journal-title":"J. Med. Chem"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1586759","DOI":"10.3389\/fimmu.2025.1586759","article-title":"Research progress of B7-H3 in malignant tumors","volume":"16","author":"Zhao","year":"2025","journal-title":"Front. Immunol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"5205","DOI":"10.1021\/acs.molpharmaceut.4c00597","article-title":"Development of a specifically labeled (89)Zr antibody for the noninvasive imaging of tumors overexpressing B7-H3","volume":"21","author":"Zheng","year":"2024","journal-title":"Mol. Pharm."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1923470\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:21:53Z","timestamp":1791264113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1923470\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":56,"alternative-id":["10.3389\/fphar.2026.1923470"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1923470","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"article-number":"1923470"}}